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Abstract
Drug delivery systems using aliphatic polyester nanoparticles are usually 
prepared via an emulsion process. These nanoparticles can control drug release 
and improve pharmacokinetics. Aliphatic polyesters are linear polymers containing 
ester linkages, showing sensitivity to hydrolytic degradation. The byproducts then 
promote autocatalytic degradation. These byproducts could enter the Krebs cycle 
and be eliminated from the body, resulting in the high biocompatibility of these 
nanoparticles. The properties of these polyesters are linked to the drug release rate 
due to biodegradation, i.e., polymer crystallinity, glass transition temperature, 
polymer hydrophobicity, and molecular weight (MW), all of which relatively influ-
ence hydrolysis. Mathematical equations have been used to study the factors and 
mechanisms that affect drug dissolution compared to experimental release data. 
The equations used as models for predicting the kinetics of drug release include 
the zero-order, first-order, Higuchi, Hixson-Crowell, and Korsmeyer-Peppas equa-
tions. Aliphatic polyester-based controlled drug delivery has surrounded much of 
the current activity in the estimation parameters of nanoparticles and stimulated 
additional research. Polymeric nanoparticles have potential in a wide range of 
applications, such as in biotechnology, vaccine systems, and the pharmaceutical 
industry. The main goal of this chapter is to discuss aliphatic polyester nanoparticles 
as drug carrier systems.
Keywords: aliphatic polyester, nanoparticles, emulsion, drug release kinetics,  
drug delivery systems
1. Introduction
Our inspiration for the examples contained within this chapter comes from 
our direct experience. Chumnanvej et al. retrospectively investigated the clinical 
outcomes of patients treated after ruptured cerebral arteriovenous malformation 
(AVM) admitted to Ramathibodi Hospital, Thailand. The results showed that 
approximately 50% and 7% of cases had symptoms of intracranial hemorrhage 
and hemorrhage associated with aneurysms, respectively [1]. A subarachnoid 
hemorrhage (SAH) is a hemorrhage that occurs in the subarachnoid space and 
leads to rupture. After cerebral surgery, these patients carry the risk of developing 
vasospasms within 4–14 days after surgery, with the peak occurring at 7 days [2]. 
Vasospasms can result from a reduction in the rapid release of blood escape from 
the cerebrum. Nicardipine hydrochloride (NCH) is a calcium channel blocker that 
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is used to treat this vascular condition; nevertheless, the half-life of NCH is approxi-
mately 8 h and provides an insufficient dose to treat vasospasms.
From a biomedical engineering point of view, polymers can be employed, 
particularly in neurosurgery, as surgical sutures, vascular grafts, stents, implants, 
tissue substitutes, or drug delivery systems. Additionally, these polymers could 
be biopolymers. Polymers must have the required physical properties and also 
be biocompatible for their intended purpose. Biopolymers are biocompatible 
polymeric materials that could be appropriate for treating certain neurosurgical 
complications. Biopolymers can respond to both the physiological and biological 
environments, and the kind of response is the main characteristic that determines 
whether the biopolymer should be used to construct biomedical devices or be 
applied in advanced neurosurgical applications. To our knowledge, there are 
three classifications of biopolymer medical-associated applications: (i) synthetic 
polymers, (ii) tissue engineering, and (iii) controlled-release agents. For cerebro-
vascular surgery applications, biopolymers have been applied to create new types of 
responsive delivery systems. This kind of polymer is needed to treat certain com-
plications during cerebrovascular surgery, such as cerebrovascular spasms. When 
polymers are fabricated as controlled-release agents, they must have the appropriate 
mechanical characteristics that are suitable for use as drug delivery agents to treat 
vasospasms [3–5].
Due to the short biological half-life of NCH, we were able to modify the NCH 
pharmacokinetics via carboxymethyl cellulose/poly(d,l-lactide-co-glycolide) 
(NCH-CMC/PLGA) nanoparticles using a contemporary emulsion process [6]. 
PLGA is an aliphatic polyester with hydrophobic properties that is highly biocom-
patible and biodegradable. The insolubility of PLGA was improved by the addition 
of CMC to increase the hydrophilicity of these nanoparticles to enhance the thera-
peutic index. These nanoparticles gave rise to a new drug delivery system that was 
capable of solving some of the major bottlenecks of the NCH-PLGA microparticles 
prepared by the double emulsion process in our previous research [7]. The NCH-
CMC/PLGA nanoparticles were flexibly designed to protect the developed delivery 
system against the drug degradation observed in the absence of a delivery system 
and improve the insufficient drug release during the first 6 days of microparticle 
treatment. These nanoparticles had a rate of drug release and a daily dose that was 
sufficient to treat vasoconstriction during the 4–14 days that this condition could 
occur. The results demonstrated that the designed aliphatic polyester nanoparticles 
had wide application prospects in drug delivery systems. These polymeric nanopar-
ticles could release drugs on demand and are easily customized depending on the 
desired application. Potentially, these same nanoparticles could be extended to 
many fields and fulfill the different purposes of delivery systems; for example, in 
the food, pharmaceutical, cosmetics, biotechnology, and sustainable agriculture 
industries. Consequently, this chapter focuses mainly on describing the core charac-
teristics of aliphatic polyester nanoparticles fabricated using an emulsion process.
2. Aliphatic polyesters
Currently, biodegradable polymers are utilized as a component of drug delivery 
systems. There are a large number of literature reports that have studied aliphatic 
polyesters, and their high biocompatibility and biodegradability potential has been 
demonstrated. Most of these polyesters have been approved for use as drug delivery 
devices by the Food and Drug Administration (FDA) [8]. Among these studies, 
aliphatic polyesters have been used to circumvent several major challenges that 
occur during drug delivery applications. In the 1960s, these polymers were initially 
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used with drug delivery systems to control drug release [9]. They can improve phar-
macokinetics by maintaining the concentration of the drug at a therapeutic level 
and minimizing side effects.
Aliphatic polyesters are linear polymers with repeating units formed through 
ester linkages (R1▬COO▬R2). They are classified into two types according to the 
structure of their repeating units, poly(alkylene dicarboxylate)s and poly(hydroxy 
acid)s, as summarized in Figure 1. Poly(alkylene dicarboxylate)s consists of two 
types of repeating units between succinic acid (HOOC▬(CH2)2▬COOH) and 
alkanediol (HO▬R▬OH) and are prepared by esterification [10, 11]. Examples 
include poly(eth ylene succinate) (PES), poly(butylene succinate) (PBS), and 
poly(butylene succinate-co-butylene adipate) (PBSA). Additionally, poly(hydroxy 
acid)s are aliphatic polyesters that have hydroxy acid (HO▬R▬COOH) repeat-
ing units that consist of carboxylic acid (▬COOH) and hydroxyl (▬OH) groups. 
These polymers can be further classified according to the bonding position of the 
hydroxyl group (α, β, or ω) in the polymer chain. As a result, these hydroxy acids 
containing hydroxyl groups can be classified as poly(α-hydroxy acid)s, poly 
(β-hydroxyalkanoate)s, and poly(ω-hydroxyalkanoate)s.
Poly(α-hydroxy acid)s have a hydroxyl group attached to the α-carbon (or 
first carbon) atom bonded to the carboxylic acid. Poly(lactide) (PLA) and 
poly(glycolide) (PGA) are members of the poly(α-hydroxy acid) family with 
repeating lactic acid and glycolic acid units, respectively. PLA has three stereo-
isomers: poly(l-lactide) (PLLA), poly(d-lactide) (PDLA), and poly(d,l-lactide) 
(PDLLA). Furthermore, poly(d,l-lactide-co-glycolide) (PLGA), another member 
of this family, is formed from a block copolymer containing both PDLLA and 
PGA [10, 12, 13]. Poly(β-hydroxyalkanoate) has a hydroxyl group bonded to the 
β-carbon of the carboxylic acid, which is the carbon atom next to the α-carbon. This 
Figure 1. 
Classification and examples of aliphatic polyesters [10].
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family includes poly(hydroxyalkanoate), i.e., poly(3-hydroxybutyrate) (P3HB), 
poly(3-hydroxyvalerate) (P3HV) and poly(3-hydroxybutyrate-co-3-hydroxyvaler-
ate) (PHBV), etc. Additionally, hydroxyl groups attached to a carbon that is three 
or more carbon atoms away from the carbonyl are poly(ω-hydroxyalkanoate)s, such 
as poly(ε-caprolactones) (PCL) [10, 13]. The ester linkages of these polymers can 
be degraded under physiological conditions, and their degradation products are 
nontoxic to human connective tissue.
2.1 Biodegradation and biocompatibility of aliphatic polyesters
The ester linkages of aliphatic polyesters are sensitive to hydrolytic attacks 
in aqueous media. The water molecules break down the long polymer chains 
into small molecules with increased water solubility. Alternatively, aliphatic 
polyesters degraded via enzymatic hydrolysis have been reported. Esterase and 
lipase are important hydrolytic enzymes that can cleave the internal ester bonds 
of these polyesters. In addition to both of these enzymes, proteases can degrade 
the members of the poly(α-hydroxy acid) family as a result of the α-ester linkages 
in their backbone [14]. These degradation products (i.e., PLA, PGA, and PLGA) 
can enter the Krebs cycle and be eliminated from the body as carbon dioxide 
(CO2) and water, resulting in the high biocompatibility of aliphatic polyesters 
[12]. Figure 2 shows the biodegradation mechanism in which these polyesters are 
converted into carbon dioxide and water.
The hydrolysis of polyesters happens in three stages. During the first stage, 
water is absorbed onto the exterior surface and matrix swelling and polymer chain 
transfer occur. This absorption results from the hydrophobic properties of aliphatic 
polyesters and leads to surface erosion. In the next stage, an amorphous region 
becomes swollen followed by stress relaxation of the polymer chain [6]. Next, the 
matrix can absorb additional water molecules via a diffusion mechanism that leads 
to the hydrolysis of the polymeric chains in the matrix, creating matrix porosity. 
After the final stage, the hydrolysis products are acid derivatives (R▬COOH), which 
are catalyzed by acids that trigger polyester hydrolysis. The parent derivatives 
can cause dissociation of the carboxyl end groups into their conjugate carboxyl-
ate anions (R▬COO−) also forming the acidic proton (H+) byproducts. The acid 
produced catalyzes the hydrolytic reaction, generating additional acid. Continuous 
mass loss occurs via the formation of these fresh acids, resulting in the autocatalytic 
degradation of the polyester. Moreover, the addition of acidic compounds (i.e., 
drugs or additives) and environmental pH can modify the rate of polymer degrada-
tion for catalytic hydrolysis [15, 16].
An example of the above process is that of PLGA degradation. Synthesized 
PLGA has two different structures, as it can be acid-terminated or ester-terminated. 
Acid-terminated PLGA and ester-terminated PLGA have end-group structures 
of carboxylic acids (PLGA▬COOH) and esters (PLGA▬COOCH3), respec-
tively. End group functionalization causes differences in PLGA biodegradation. 
Figure 2. 
Hydrolytic degradation of aliphatic polyesters.
5
Aliphatic Polyester Nanoparticles for Drug Delivery Systems
DOI: http://dx.doi.org/10.5772/intechopen.100977
Acid-terminated PLGA is degraded rapidly in comparison with the more hydropho-
bic ester-terminated PLGA. Carboxylic end-capped PLGA can be used as an acid 
to initiate autocatalytic degradation; thus, these acids have been applied to catalyze 
acid hydrolysis and promote autocatalytic degradation. Therefore, acid-terminated 
PLGA hydrolyzes the ester linkages more easily than ester-terminated PLGA as a 
result of the carboxylic end groups that are capable of producing acidic byproducts, 
as shown in Figure 3 [17].
Furthermore, the rate of degradation of PLGA is dependent on the PDLLA:PGA 
ratio as determined by the weight percentages of PDLLA and PGA, such as 50:50, 
65:35, 75:25, and 95:5. The decelerated degradation of PLGA occurs at a high amount 
of PDLLA, whereas a higher amount of PGA indicates rapid degradation. PDLLA, 
with methyl groups in its structure, has reduced chain mobility (chain configura-
tion), leading to more hydrophobicity than PGA, which is devoid of these methyl 
groups (Figure 1). PGA is a highly hydrophilic polymer that can absorb more 
water molecules [6, 13]. Thus, PGA hydrolysis is more complimentary than PDLLA 
hydrolysis. As a rule, the drug release of PLGA is affected by the biodegradation of 
PDLLA and PGA. A 50:50 ratio of PDLLA:PGA has been shown to prompt degrada-
tion and produce higher rates of drug release [18, 19].
2.2 The properties of aliphatic polyesters properties in delivery systems
Following an earlier example, these differences in chemical structure illustrate 
how the changes in the physicochemical properties of the polymers are linked to 
the drug release rate via aliphatic polyester biodegradation. The biodegradation 
characteristics are controlled by polymer crystallinity, glass transition temperature 
(Tg), polymer hydrophobicity, and molecular weight (MW), all of which influence 
hydrolysis.
2.2.1 Polymer crystallinity
The crystalline regions of polymers consist of regular and orderly arranged 
polymeric chains that result in nanoparticles with high drug-loading abilities. 
Highly crystalline polymers present difficult mass transfer of both water and 
drug molecules. Water molecules are strongly absorbed and restricted within the 
Figure 3. 




orderly polymeric chains of the crystalline regions, leading to a lower swelling rate. 
Crystalline polymer regions are resistant to hydrolysis compared to amorphous 
regions [16, 20]. As a result, the crystalline regions display delayed degradation. 
The byproducts of later hydrolysis still contain a very large number of high MW 
compounds in the polymer in the matrix, resulting in a high degree of chain 
entanglement. Polymer chain entanglement has an important effect on the drug 
release rate. High amounts of entanglement cause the drug release rate to be slower 
than that of highly disordered amorphous polymer materials.
2.2.2 Tg
The Tg value may impact the kinetics of drug release from delivery systems. For 
instance, PLGA micro/nanoparticles were prepared via the emulsion solvent evapo-
ration method [6, 7, 21–23]. The residual solvent was removed via evaporation to 
harden the nanoparticles. Solvent evaporation promotes the transition to the glassy 
state from the rubbery state, as observed by hardening. As a result, the removal 
of solvents is comparable to the glass transition caused by reducing the tempera-
ture below Tg. Additionally, drug loading in micro/nanoparticles can decrease 
Tg through plasticizing effects. Increased drug loading leads to drug dispersion 
throughout the polymeric matrix, which increases the distance between polymeric 
chains. This causes the free volume to increase and reduces the Tg of the polymer 
[23]. The formation of glassy PLGA affects delivery systems by, for example, 
lowering the elastic modulus and transfer rates of water and the drug molecules and 
slowing the degradation and drug release rates. In comparison, the formation of 
the rubbery state facilitates higher mass transfer rates, and a higher elastic modulus 
leads to faster degradation and drug release rates.
2.2.3 Polymer hydrophobicity
The hydrophobicity of aliphatic polyesters is key to their hydrolytic degradation. 
When aliphatic polyesters are more hydrophobic, they are less water-sensitive and 
less susceptible to ester linkage hydrolysis than more hydrophilic polyesters. This 
causes a decrease in nanoparticle swelling, which results from the low water uptake. 
These polymers have high hydrolytic resistance and a slower degradation rate. 
Additionally, a large number of entanglements causes a slower release rate.
2.2.4 Polymer MW
The MW of a polymer is the molecular mass of its polymeric chains and affects 
the delivery system properties. High MW polymers have a large amount of chain 
entanglement and low chain mobility. Compared with low MW polymers, high 
MW polymers show the benefits of lower mass transfer rates, a lower swelling rate, 
a lower elastic modulus, and reduced solubility. Low MW polymers have a reduced 
number of polymeric chain entanglements, leading to greater molecular mobility. 
Water molecules can be comfortably absorbed in the polymeric matrix of these 
low MW polymers, resulting in faster hydrolytic degradation and a faster drug 
release rate.
3. Polymeric nanoparticle drug delivery systems
Nanoparticles in drug delivery systems normally have sizes ranging from 1 to 
1000 nm. In essence, nanoparticles with sizes in this range have a high surface 
7
Aliphatic Polyester Nanoparticles for Drug Delivery Systems
DOI: http://dx.doi.org/10.5772/intechopen.100977
area to volume ratio and their behavior in the body could cause increases in the 
absorption potential and cytotoxicity as the expanded surface is proportional to 
cytotoxicity [24]; thus, these nanoparticles could potentially lead to an increase in 
cytotoxicity. Nevertheless, nanoparticles prepared from aliphatic polyesters could 
possibly lead to a reduction in cytotoxicity, as they are highly biocompatible and 
biodegradable. Aliphatic polyester nanoparticles play key roles in improving the 
pharmacokinetics, drug bioavailability, specific delivery at the site of action, and 
stability in the bloodstream. Their high surface area can adsorb drug molecules and 
encapsulate a large number of drugs in their matrix, effectively carrying drugs, 
proteins, DNA, and organs. Therefore, the development of aliphatic polyester 
nanoparticles is one of the most successful ideas for drug delivery innovation.
3.1 Polymeric nanoparticles
Polymeric nanoparticle delivery systems refer to both nanospheres and nano-
capsules. Their classification is based on the positional characteristics of the drugs 
and polymers, as shown schematically in Figure 4a and b. Nanospheres contain 
drug molecules within a uniformly dispersed polymeric matrix, while nanocapsules 
entrap the drug molecules inside their core, a cavity surrounded by a polymeric 
membrane that acts as a shell [25].
Regarding the molecular orientation surface, we propose a possible schematic 
of the polyester chain on the nanoparticle surface as shown in Figure 4. In the 
case of PLGA nanospheres, the polymeric chains ignore water molecules, which is 
consistent with computational simulation results that demonstrated that PLGA is 
strictly hydrophobic [26]. At both the surface and interface, the carbon backbones 
clump together rather than being distributed in the aqueous solution. This causes 
the hydrophobic molecules to have minimal contact with hydrophilic molecules. On 
the other hand, the oxygen atoms of the hydroxyl groups (▬OH), carboxylic acids 
(▬COOH), and ester groups (▬COO▬) interact with the water molecules resid-
ing near the water-PLGA interface, and the hydrogen atoms in the polymer chain 
resemble the oxygen atoms. Hydrophobic drugs display the tendency to accumulate 
Figure 4. 
Schematic representation of the structures and molecular orientations of PLGA nanospheres (a), PLGA 




on the surface, with a few drug molecules migrating to the core, leading to the 
uniform distribution of drug molecules within the polymeric matrix, especially in 
the vicinity of the nanosphere surface (Figure 4a). The nanocapsules have contact 
with both the inner and outer aqueous solutions. Thus, the molecular orientation 
of aliphatic polyesters on the inner and outer membrane surfaces corresponded 
to nanospheres. Nevertheless, the hydrophilic drugs tend to be entrapped inside 
the core of a cavity surrounded by the polymeric membrane due to the insolubility 
between the drug and the polymer (Figure 4b).
3.2 Polymeric nanoparticle preparation
The preparation of nanospheres and nanocapsules follows an uncomplicated 
basic principle, the emulsification solvent evaporation method. The guiding 
principles are that the drug and polymer dissolve in each other during nanosphere 
preparation. As a result, the drug molecules are uniformly distributed in the poly-
meric matrix. Examples of hydrophobic drugs with hydrophobic polymers were 
previously discussed in the section on nanosphere molecular orientation. However, 
nanocapsules are prepared from drugs and polymers that are essentially insoluble 
in each other. This property promotes the formation of core-shell structures to 
load drugs.
The preparation of both types of nanoparticles depends upon drug solubility 
and polymer solubility. Therefore, drug solubility is a strict limitation in the use 
of aliphatic polyesters, as drug solubility affects the type of nanoparticles that can 
be prepared because polyesters are hydrophobic polymers. This indicates that the 
use of water-soluble drugs could produce nanocapsules, but insoluble drugs yield 
nanospheres. In addition to drug solubility, nanoparticles of aliphatic polyesters 
can be easily prepared. This section describes the preparation of nanoparticles via 
emulsification methods for these polyester-controlled drug delivery systems.
3.2.1 Single emulsion method
Oil-in-water emulsification (O/W emulsion) can be used to prepare nano-
spheres that are ideal for entrapping hydrophobic drugs (i.e., steroids) [19] or 
water-soluble drugs entrapped on nanosphere surfaces [27]. Examples include 
amoxicillin-loaded PCL micro/nanospheres modified surface by chitosan for 
antibacterial applications. The amino groups (▬NH3+) of chitosan interact with 
PCL via carboxylate anions (▬COO−) on the micro/nanosphere surface. Amoxicillin 
is encapsulated by the electrostatic interactions between the negative charges of 
the drug and the residual positive charge on the surface of chitosan, as observed 
by the zeta potential values of −20.03 mV and +53.93 mV, respectively. This study 
varied the ratios of PCL:chitosan to be 1:1, 1:3, and 1:5, and the results showed that 
increasing the ratio improved the encapsulation efficiency (~73–83%) and  
controlled drug release (~5.76–6.56 mg) over 7 days compared to amoxicillin-
loaded PCL micro/nanospheres, which showed rapid drug release within 12 h due 
to the low encapsulation efficiency (~5.4%). Additionally, the amoxicillin-loaded 
PCL micro/nanosphere modification inhibited microbial growth, but the chitosan-
free micro/nanospheres were less effective [27].
3.2.2 Double emulsion method
Water-in-oil-in-water (W1/O/W2) double emulsions could be used to prepare 
nanocapsules for the loading of water-soluble molecules, such as hydrophilic drugs, 
proteins, peptides, and vaccines [19]. This system is an extraordinarily complex 
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dispersion system of liquid membranes. In addition, the contemporary W1/O/W2 
double emulsion method led to the preparation of PLGA nanocapsules. This emul-
sion method can enhance the solubility of poorly soluble drugs in the medium. 
As mentioned previously in the introduction, we prepared NCH-CMC/PLGA 
nanocapsules via a contemporary emulsion process. The composition of phase W1 
included NCH and CMC. Notably, NCH dissolves in citric acid solution, but CMC 
is insoluble in acidic solutions, as citric acid is a crosslinking agent of CMC. This 
method fabricated two systems, citric acid crosslinking droplets and CMC droplets. 
To generate the crosslinking droplets, solid NCH was first dissolved in citric acid 
mixed poly(vinyl alcohol) (PVA) solution (W1). This solution was then added to 
an organic solution of PLGA with stirring (O). Similarly, the CMC solution (W1) 
was added to PLGA solution with stirring, forming CMC droplets. Both droplets 
were added together and ultrasonicated to form crosslinked droplets (W1/O single 
emulsion). This single emulsion was again added and ultrasonicated, forming the 
W1/O/W2 double emulsion. This unique synthesis enhanced the drug loading of 
the nanoparticles for controlled drug release for up to 16 days. As a result, NCH-
CMC/PLGA nanoparticles containing calcium channel blockers were created. This 
method paved the way to generate a treatment for the prevention of vasospasm 
complications after surgery for ruptured intracranial aneurysms. There are several 
applications for calcium channel blocker prolonged-release implants. This applica-
tion involves the binding of calcium channel blockers in composite polymer formu-
lations for slow release at a rate that is effective to treat cerebral vasospasm in animal 
models. This drug delivery system is objectively locally positioned at the surgical site 
after the intracranial aneurysm is secured. These nanoparticles are located around 
the inflamed vessels and can avoid being washed away. The strategy for controlled 
release is based on polymer degradation at a rate that is effective for the treatment of 
cerebral vasospasms for 4–14 days. However, a clinical scenario needs to be investi-
gated in the future [6].
3.3 Polymeric nanoparticle stabilization
Stabilizing the produced nanoparticles is a key factor in the delivery systems 
because the nanoparticles need to protect the encapsulated drugs from degradation. 
Agglomeration and flocculation are the destruction methods of nanoparticles and 
can produce macroscopic lumps that lead to the diffusion of drug molecules and 
their degradation in the residence environment. To stabilize these nanoparticles, 
an emulsion stabilizer is required, and this can be efficiently accomplished with 
amphiphilic molecules. These molecules contain two components, a hydrophilic 
part, and a lipophilic side. Typical examples of amphiphilic molecules include Span 
80 and Tween 80 as nonionic emulsifiers. Additionally, anionic emulsifiers, cationic 
emulsifiers, and zwitterionic emulsifiers provide structural diversity.
The most commonly used rule for emulsifier selection is the hydrophilic-
lipophilic balance (HLB) scale (HLB scale ranges from 0 to 20). This scale indicates 
the relative fraction of hydrophilic to lipophilic parts within the emulsifier molecule. 
High HLB values (8.0–18.0) are more suitable for use in O/W emulsions because 
they have a higher degree of hydrophilicity. In this case, O/W emulsions with a large 
amount of water are required to allow the formation of polymer dispersion droplets. 
As a result, these emulsifiers can widely expand the applications of the hydrophilic 
molecule for nanoparticle isolation, which then leads to interrupted agglomeration. 
Emulsifiers that have HLB values between 3.5 and 6.0 are most commonly used 
in W/O emulsions because they are more lipophilic [28, 29]. Figure 4c illustrates 
the expansion of the hydrophilic molecules of Span 80 (HLB = 4.3) and Tween 80 
(HLB = 15.0) [7] at the interface of dispersed polymer droplets.
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Furthermore, polymers have been used as emulsion stabilizers during emulsifier 
preparation methods, i.e., PVA, chitosan, and alginate [22, 30]. High MW polymers 
(>10 kDa) show driving forces that are equivalent to or greater than van der Waals-
London (VDWL) forces. These VDWL forces are the primary source of attraction 
between nanoparticle surfaces and cause them to clump together. Through the addition 
of polymers, the polymeric chains can stabilize the nanoparticles via electrostatic, ste-
ric, and depletion forces. Electrostatic stabilization can be applied to charged polymers 
based on the simple principle that similar electric charges repel each other. Nanoparticle 
surfaces with zeta potential values greater than +30 mV or less than −30 mV are nor-
mally considered stable, as presented in Figure 5a. Steric stabilization is achieved on the 
surfaces of nanoparticles via adsorbed or chemically attached nonionic/ionic polymers. 
These uncharged polymers have a steric barrier due to a long chain that prevents the 
nanoparticles from sticking together (Figure 5b). Moreover, the addition of a high 
concentration of polymer for stabilization could lead to a high amount of free polymer 
in the dispersion medium. These free polymers establish repulsive forces between 
the nanoparticles to prevent nanoparticle aggregation and act as depletion stabilizers 
(Figure 5c) [31].
For example, PVA is an uncharged polymer that is commonly used as an emul-
sion stabilizer for the preparation of PLGA nanoparticles. The hydroxyl groups on 
the PVA chains are adsorbed at the interface with the PLGA chains via the hydroxyl, 
carboxylic acid, and ester groups. The interface between PLGA and PVA is an area 
with strong interactions, resulting in high nanoparticle stabilization [32, 33]. This 
interaction corresponds to the molecular orientation of PLGA nanospheres and 
PLGA nanocapsules (Figure 4). Figure 5d proposes a schematic representation of 
the molecular orientation of PVA at the surface of PLGA nanoparticles.
The use of polymers as stabilizers affects the characteristics of the nanoparticles 
to a greater extent than the use of other emulsifiers; as a result, these nanoparticles 
have a high MW. As a result, the use of low MW polymers or polymers at a low 
concentration results in reduced stability, lower drug loading, a rapid release rate, 
and a smaller size compared with high MW polymers or polymers present in high 
concentrations [6]. In addition, the charged polymers affect aliphatic polyester 
Figure 5. 
Schematic representation of the molecular interactions of electrostatic stabilization (a), steric stabilization  
(b), depletion stabilization (c), and PVA at the surface of PLGA nanoparticles (d), based on information from 
a review article [31–33].
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nanoparticles. Alginate is an anionic polymer and contains carboxylate anions 
(▬COO−) on its polymer chains. These anions repel the anions of the aliphatic 
polyesters, resulting in a larger size and permitting an increase in the retention of 
cationic drugs. However, cationic polymers (i.e., chitosan with a ▬NH3+ groups) 
interact with the carboxylate anions of the stabilizing polymers, leading to reduced 
particle size and increased retention of anionic drugs [30].
3.4 Mathematical models of drug release
Mathematical knowledge could assist in clarifying the drug release mechanism 
from polymer-based nanoparticles for controlled delivery. The exact mass transport 
and the relationship between drug release as a function of time can be described 
through various mathematical models. These models are able to predict analytics 
via data obtained from the drug release experiments to explain drug release kinet-
ics. The coefficient of determination (R2) and adjusted coefficient of determina-
tion (adj.-R2) are investigated by statistical analysis to determine the relationship 
that the equation explains. The highest values of R2 and adj.-R2 from curve fitting 
involving describing the optimal relations (maximum accuracy) as a function of 
release time can be predicted with these Equations [6, 21]. This chapter will discuss 
some of the most commonly used equations to predict the kinetics of release from 
polymeric nanoparticles, including the zero-order, first-order, Higuchi, Hixson-
Crowell, and Korsmeyer-Peppas equations, as summarized in Table 1.
When predicting drug release rates, the zero-order model represents controlled 
drug release that occurs at a constant rate depending on only the time and is 
independent of the amount of polymer. In the first-order model, the amount of drug 
released tends to depend on the polymer concentration, which affects the swelling 
and porosity of the nanoparticles. The Hixson-Crowell model describes the rate of 
drug release according to the cube root of its volume, in which matrix dissolution 
occurs. As a result, the diameter and surface area of the nanoparticles decreases 
proportionally over time according to the cube root of the weight at that particular 
time [34]. The Higuchi model predicts the release rate via diffusion control based on 
Fick’s first law, which is square root time-dependent (t1/2) [35].
Generally, the release mechanism can be predicted by the Korsmeyer-Peppas 
model. This model determines the exponential relationship between the rate of drug 
release and time. It is based on polymeric matrices with different geometries, fol-
lowing the released exponential (n). The exponential n-value indicates three types 
Model Equation Graphical representation







log cumulative remaining vs time
Hixson-Crowell 1/3 1/3
0 t HXM M K t- = Cumulative remaining
1/3 vs time
Higuchi 1/2
t HQ K t= Cumulative release vs time
1/2
Korsmeyer-Peppas
t KPlogQ nlogt logK= + log cumulative release vs log time
Qt is the cumulative amount of drug release at time (t), Q0 is the initial amount of drug release at (t0), Mt is the 
cumulative amount of drug remaining at time (t), M0 is the initial amount of drug remaining at (t0), t is time, n is the 
released exponent of Korsmeyer-Peppas, and K0, K1, KHX, KH, and KKP are the zero-order, first-order, Hixson-Crowell, 
Higuchi, and Korsmeyer-Peppas constants, respectively.
Table 1. 
Mathematical models of drug release [6].
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of release mechanisms (Figure 6). The first type is the mechanism of Fickian diffu-
sion, where the rate of diffusion of drug release is considerably greater than the rate 
of polymeric chain relaxation. The second mechanism is anomalous transportation 
via diffusion and swelling/erosion via slow rearrangement of polymeric chains. 
The final type is only the swelling/erosion mechanism. The release mechanisms of 
swelling and erosion are affected by an expansion in porosity and polymeric chain 
cleavage, respectively. Thus, the anomalous transportation and swelling/erosion 
mechanisms are both non-Fickian diffusion [36].
Using equations to predict release mechanisms can be confusing. Therefore, 
we proposed the flowchart sequence of use steps for these equations to describe 
drug release from PLGA nanoparticles [6]. The initial step investigates whether 
the rate of drug release is independent or dependent on the various concentra-
tions by comparing R2 values between the zero-order and first-order models. Next, 
the Hixson-Crowell equation and Higuchi equation were compared to determine 
whether the release rate depends on the probability of matrix dissolution or is 
diffusion controlled. Finally, the mechanism of drug release was investigated via 
the Korsmeyer-Peppas equation to determine the exponential n-value, as proposed 
in Figure 6.
3.5  Estimation of the formulation parameters for the polymeric nanoparticle 
system
Nanoparticles are one of the best choices of novel delivery systems because of 
their ease of preparation and long shelf life. Nanoparticle systems have fascinating 
physical properties that have been recognized over a wide range of utilizations. The 
characterization of different formulation parameters of nanoparticles is considered 
in the following sections.
3.5.1 Physical appearance
The physical appearance of nanoparticles can be examined visually for optical 
clarity, homogeneity, and fluidity, and also microscopically using a scanning elec-
tron microscope [37]. Figure 7 illustrates digital photographs of PLGA nanopar-
ticles [6] compared to PLGA microparticles [7] prepared via an emulsion process. 
Due to the optical transparency, the nanoparticles appeared as more transparent 
dispersions than the microparticles, which appeared white.
Figure 6. 
Flowchart sequence of the steps used for the equations that predict drug release.
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3.5.2 Rheology
Nanoparticles have high surface energy, resulting in agglomeration. In particular, 
aliphatic polyester-based nanoparticles rapidly agglomerate due to the strong inter-
actions between the hydroxyl, carboxylic acid, and ester groups of the polymeric 
structures interacting with other nanoparticles. This behavior promotes the nanopar-
ticles to be dispersed in media, affecting the rheological properties, such as viscosity 
and yield stress, of the suspension. Rheological characteristics can be examined with 
a Brookfield viscometer. The rheological properties show the nanoparticle region and 
its separation from other regions and play a principal role in stability [37, 38].
3.5.3 Particle size, polydispersity, and zeta potential
Dynamic light scattering is used to investigate particle size, zeta potential, and 
fluctuations in the intensities of scattering of particles due to Brownian motion. 
This technique also analyzes the polydispersity index to measure the wideness of 
the size distribution and quality of the dispersion [39, 40].
3.5.4 Drug stability
The stability of nanoparticles can be measured via visual inspection in closed 
tubes at both room temperature and elevated temperatures. Each month, the 
nanoparticles can be evaluated based on their phase separation, % transmittance, and 
globule size [7, 41]. Examples include PLGA nanoparticle dispersions [6] compared 
to PLGA microparticle dispersions [7] in phosphate-buffered saline (pH 7.4 at 37°C) 
to mimic the physiological environment. The nanoparticle suspension presented no 
phase separation, suggesting that these nanoparticles did not precipitate (Figure 7a). 
The microparticles could have a higher gravitational force relative to the nanopar-
ticles, leading to their easy precipitation, which can be observed from the phase 
separation of the microparticle solution (Figure 7b). Therefore, drug administration 
of these microparticles needs to carry a “shake well before use” label [22].
3.5.5 Drug solubility
Excess drug was added to the nanoparticles to optimize the formulation, similar to 
the optimization of the other ingredients. The nanoparticles were continuously stirred 
Figure 7. 
SEM micrographs and digital photographs of PLGA nanoparticles (a) and PLGA microparticles (b) prepared 
via an emulsion process [6, 7].
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for 24 h at room temperature, and samples were removed and centrifuged at 600 rpm 
for 10 min at predetermined time points. The quantity of soluble drugs in the opti-
mized nanoparticles was determined by calculating the amount of drug present in the 
residue and comparing it with the total amount of added drug. The individual ingredi-
ents were used for comparison of the solubility of the drug in the nanoparticles [7, 42].
3.5.6 In vitro, ex vivo, and in vivo drug release
In vitro and in vivo studies provide extrapolated data to reflect the bioavailability 
of drug formulations. The in vitro drug release profile of nanoparticles can be 
determined with a Franz diffusion cell. The donor compartment has a cellophane 
membrane as a barrier, comprising the encapsulated drug in the nanoparticles. The 
receptor compartment is filled with buffer solution, usually phosphate-buffered 
saline (pH 7.4), and the system is stirred with a magnetic stirrer at 100 rpm and 
37°C. At predetermined time intervals, samples of the dispersion are withdrawn 
from the medium of the receptor compartment and an equal amount of medium 
is returned to the system at this same time. The withdrawn sample is filtered using 
a 0.22–50 μm filter (e.g., Millipore, USA) and analyzed for drug release using 
UV-visible spectrophotometry at the specific wavelength that shows peak absorp-
tion of the drug [39, 43, 44].
An ex vivo drug release study profile of nanoparticles can be performed with 
a diffusion cell. Suitable skin and the underlying cartilage removed from ears can 
be cut up and placed on the diffusion cell filled with receptor solution. Vesicular 
process samples are placed on the dorsal surface of the skin. At predetermined time 
intervals, samples of the dispersion are withdrawn from the medium of the recep-
tor compartment and an equivalent amount of the medium is returned at the same 
time. The withdrawn sample is then analyzed for the amount of drug released using 
high-performance liquid chromatography (HPLC) or UV-visible spectrophotom-
etry at a specific wavelength [44].
In vivo, drug release study profiles of nanoparticles can be carried out by admin-
istering the nanoparticles to living animals. At predetermined time intervals, blood 
samples are withdrawn, followed by centrifugation and analysis of drug release 
using HPLC.
3.6 Applications of polymeric nanoparticle systems
Nanoparticle systems have been used as delivery vehicles in a variety of drug 
delivery systems for controlled release because of their potential to solubilize active 
agents. Aliphatic polyester nanoparticles have various goals, which are accom-
plished in different ways, as outlined in the following sections.
3.6.1 Oral delivery
Nanoparticle formulations have many benefits over conventional oral delivery 
methods, including increased absorption, minimized drug toxicity, enhanced oral 
bioavailability, and excellent clinical potency. Hence, nanoparticle systems have 
been modified for use in drug delivery systems for compounds such as oral drugs, 
steroids, hormones, diuretics, and antibiotics [40, 45, 46].
3.6.2 Parenteral delivery
Parenteral delivery via the intravenous route has been used for controlled drug 
delivery and drug targeting to particular sites. Aliphatic polyester nanoparticles 
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significant in the parenteral delivery system since they can improve drug solubil-
ity, long-term stability in the body, biocompatibility, and ease of development for 
delivery to a targeted site. Nanoparticle formulations have prominent advantages 
over other systems. Additionally, fine nanoparticles are cleared more slowly than 
coarse particles [47, 48].
3.6.3 Topical delivery
Hydrophilic and lipophilic drugs poorly penetrate the skin due to the limita-
tions of their solubility in both the lipid phase and aqueous solution. The topical 
delivery of drugs via nanoparticle formulations has several advantages over other 
conventional topical methods for the treatment of skin disorders while showing 
minimal side effects. Nanoparticles can incorporate both lipophilic and hydrophilic 
drugs. Additionally, drug degradation, salivary degradation, and hepatic first-pass 
metabolism in the stomach can be avoided, while benefiting from sustained drug 
delivery, long-term stability, enhanced permeability, and reduced toxicity [49, 50].
3.6.4 Pulmonary drug delivery
The treatment of lower respiratory infections is difficult due to the presence 
of microbes deep in the respiratory system. Nanoparticles as a targeted drug 
delivery system to the site of infection have been actively applied to enhance 
antimicrobial drug resistance, sustain drug release, and increase bioavailability. 
Importantly, nanoparticle systems that contain multiple antimicrobial substances 
can be used [51, 52].
3.6.5 Vaccine delivery
Recently, there have been many research topics related to nanoparticles as car-
riers for vaccines. The main idea is to use the nanoparticle as an effective carrier to 
deliver an inactivated organism to the membrane to stimulate the immune system. 
One study found that it is possible to generate genital mucosa immunity from 
vaccines that are added to the nasal mucosa. The synthesized proteins passed into 
the mucosal membrane surface by using nanoparticles to absorb the antigen using 
adjuvant facilitation [53–55].
There are several mechanisms to load antigens into the nanoparticles, such as 
encapsulation, encapsulation with coating, encapsulation with targeting, physical 
adsorption, chemical conjugation, and conjugation with a targeting mechanism. 
Hydrophobic interactions are known to be effective ways to load antigens into 
nanoparticles by physical adsorption processes, which apply weak interactions to 
dissociate antigens and nanoparticles in the body. During protein synthesis, the 
encapsulated antigens are mixed with nanoparticle precursors, which is a conse-
quence of the release of the encapsulated antigen when the nanoparticle degrades 
in vivo.
The first clinical trial application received was for the use of nanoparticles for 
influenza and human immunodeficiency virus (HIV) proteins. A recombinant HIV 
glycoprotein 120 (HIV-gp120) antigen mix in nanoparticles was studied in mice and 
guinea pigs by intranasal immunization and demonstrated a robust serum anti-
gp120 immunoglobulin G (IgG) response [53]. The constituent of Prepandrix® has 
been approved for the use of the flu vaccine AS03 (an adjuvant system containing 
α-tocopherol and squalene in an oil-in-water emulsion) during the influenza pan-
demic. AS03 has been used as a reference for other vaccines, such as Arepanrix®, to 
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The balance between immunogenic benefits and safety needs to be considered 
and is achieved by selecting the correct adjuvant, antigen, and emulsion composi-
tion. These factors are considered the main factors of concern during vaccine 
development, as they directly affect the benefit-risk balance. Vaccine efficiency 
is vital, and this factor is the major element controlling pandemics through the 
selection of the correct oil composition, adjuvant, surfactant, and antigen for the 
specific disease.
Aliphatic polyester-based nanoparticles could be delivered as adjuvants for 
vaccines during the coronavirus disease 2019 (COVID-19) pandemic [56, 57]. 
Polymers are the main material for vaccine delivery. For example, the most popular 
aliphatic polyesters have been used in vaccine adjuvants for lymph nodes target-
ing HIV, Bacillus anthracis, Chlamydia trachomatis, and malaria [58]. Moreover, 
the addition of a poly(ethylene glycol) (PEG) coating around PLA (PEG-PLA) 
nanoparticles has been found to facilitate the transport of the antigen of tetanus 
toxoid to the rat nasal epithelium for nasal vaccine delivery [59].
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